Amneal Pharmaceuticals (2DT) Stock Overview
A global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
2DT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Amneal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.40 |
| 52 Week High | US$14.90 |
| 52 Week Low | US$6.55 |
| Beta | 1.26 |
| 1 Month Change | 0.70% |
| 3 Month Change | 39.81% |
| 1 Year Change | 105.71% |
| 3 Year Change | 441.35% |
| 5 Year Change | 297.79% |
| Change since IPO | -21.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2DT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -2.5% |
| 1Y | 105.7% | 43.9% | -0.6% |
Return vs Industry: 2DT exceeded the German Pharmaceuticals industry which returned 43.9% over the past year.
Return vs Market: 2DT exceeded the German Market which returned -0.6% over the past year.
Price Volatility
| 2DT volatility | |
|---|---|
| 2DT Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 2DT has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2DT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 8,700 | Chirag Patel | www.amneal.com |
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
Amneal Pharmaceuticals, Inc. Fundamentals Summary
| 2DT fundamental statistics | |
|---|---|
| Market cap | €4.75b |
| Earnings (TTM) | €106.99m |
| Revenue (TTM) | €2.67b |
Is 2DT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2DT income statement (TTM) | |
|---|---|
| Revenue | US$3.05b |
| Cost of Revenue | US$1.85b |
| Gross Profit | US$1.19b |
| Other Expenses | US$1.07b |
| Earnings | US$122.12m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 0.38 |
| Gross Margin | 39.16% |
| Net Profit Margin | 4.01% |
| Debt/Equity Ratio | 6,438.6% |
How did 2DT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/12 14:13 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| David Buck | B. Riley Securities, Inc. |